Mastocytosis Clinical Trial
Official title:
Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study With PA101 in Patients With Indolent Systemic Mastocytosis
Verified date | September 2016 |
Source | Patara Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Federal Institute for Drugs and Medical Devices |
Study type | Interventional |
This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in
adult patients with indolent systemic mastocytosis (ISM).
The purpose of the study is to determine the efficacy and safety profile of PA101 delivered
via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using
standard treatments.
Status | Completed |
Enrollment | 41 |
Est. completion date | June 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of indolent systemic mastocytosis (ISM) according to the WHO criteria and the consensus proposal (2001) - Experiencing at least one predefined qualifying symptom in at least two organ systems within 3 months of Screening despite the use of H1 and/or H2 antihistamines and other anti-mediator therapy - Experiencing symptoms with a severity score of at least 4 for at least 7 out of 14 days during the Run-in period with at least one predefined qualifying symptom each from at least two organ systems, despite the use of H1 and/or H2 antihistamines and/or other anti-mediator therapy - Willing and able to use an eDiary device daily for the duration of the study - Completed at least 5 eDiary reports during each of two consecutive weeks of the Run-in period - Willing and able to provide written informed consent prior to any study procedures Exclusion Criteria: - Advanced systemic mastocytosis (i.e., aggressive systemic mastocytosis [ASM], mast cell leukemia [MCL], or systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease [SM-AHNMD] ) - Current or recent history of clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, malignant, or other illnesses that could put the patient at risk or compromise the quality of the study data as determined by the Investigator - Use of oral cromolyn sodium within 6 weeks of Screening - History of systemic corticosteroid, immunosuppressive, or anti-IgE monoclonal antibody therapy (e.g., omalizumab) within 6 months of Screening - History of anaphylaxis requiring systemic treatment (i.e., corticosteroid or epinephrine) within 12 months of Screening - Upper or lower respiratory tract infection within 4 weeks of Screening - History of malignancy within the last 5 years, except basal cell carcinoma or cervix carcinoma in situ - Major surgery within 6 months of Screening - Current or recent history (within 12 months) of excessive use or abuse of alcohol - Current or recent history (within 12 months) of abusing legal drugs or use of illegal drugs or substances - Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study - Participation in any other investigational drug study within 4 weeks of Screening - History of hypersensitivity or intolerance to aerosol medications or cromolyn sodium |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hopital Necker - Enfants Malades | Paris | |
Germany | Charité - Universitätsmedizin Berlin | Berlin | |
Germany | Klinikum Darmstadt | Darmstadt | |
Germany | University Medical Center Mainz | Mainz | |
Germany | Technical University München | Munich | |
Italy | University of Salerno | Salerno | |
Netherlands | University Medical Center of Groningen | Groningen | |
Spain | Hospital Universitario de Fuenlabrada | Madrid |
Lead Sponsor | Collaborator |
---|---|
Patara Pharma |
France, Germany, Italy, Netherlands, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall symptom score | Mastocytosis Activity of Symptoms (MAS Plus) questionnaire for daily symptom score using eDiary | 6 weeks | No |
Secondary | Disease specific quality of life (QoL) | Mastocytosis Impact Questionnaire (MIQ) for quality of life | 6 weeks | No |
Secondary | Patient Global Impression of Change (PGIC) scale | 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01333293 -
The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01481909 -
Study on Mastocytosis for Rupatadine Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT00044122 -
Study of Factors Regulating Mast Cell Proliferation
|
||
Recruiting |
NCT06440148 -
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
|
||
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Not yet recruiting |
NCT05084872 -
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01701843 -
Cromoglicate in Mastocytosis
|
Phase 2 | |
Completed |
NCT00831974 -
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
|
Phase 2 | |
Completed |
NCT00047918 -
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
|
N/A | |
Completed |
NCT00006413 -
Stem Cell Transplantation to Treat Systemic Mastocytosis
|
Phase 2 | |
Completed |
NCT00050193 -
Cause and Natural Course of Pediatric-Onset Mastocytosis
|
||
Completed |
NCT02620254 -
Mast Cell Connect: A Registry for Patients With Mastocytosis
|
||
Completed |
NCT00255346 -
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
|
Phase 2 | |
Completed |
NCT00001356 -
Characteristics of Mast Cells in Mastocytosis
|
N/A | |
Recruiting |
NCT06466889 -
Mastocytosis Registry (of Zurich)
|
||
Recruiting |
NCT05186753 -
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
|
Phase 2 | |
Recruiting |
NCT02450396 -
Pregnancy and Medically Assisted Conception in Rare Diseases
|
||
Completed |
NCT00038675 -
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
|
N/A | |
Not yet recruiting |
NCT06432556 -
Study of Cellular Heterogeneity in Patients With Mastocytosis
|
N/A | |
Completed |
NCT00336076 -
Molecular Mechanisms and Diagnosis of Mastocytosis
|
N/A |